On January 26, Ge Longhui Medical (688310.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected to achieve operating income of about 48,0926,800 yuan in 2023. Compared with the same period last year (statutory disclosure data), it will increase by about 97.437 million yuan, an increase of about 25.41% over the previous year. It is estimated that in 2023, net profit attributable to owners of the parent company will be around RMB 103.3845 million. Compared with the same period of the previous year (statutory disclosure data), it will increase by about RMB 36.3579 million, an increase of about 54.24% over the previous year. It is estimated that in 2023, net profit attributable to the owners of the parent company after deducting non-recurring profit and loss will be around 89.1013 million yuan. Compared with the same period last year (statutory disclosure data), it will increase by about 31.4976 million yuan, an increase of about 54.68% over the previous year.

In 2023, the company coordinated planning and orderly production according to orders, and the company carried out continuous technological innovation and process improvements to continuously enhance the company's competitiveness. New products such as glass pre-filled syringe cleaning and silicification packaging machines, glass pre-filled syringe needle insertion machines, and disposable syringe pre-assembled stacking machines were sold in the main business revenue. Products such as automatic dialyzer assembly lines, automatic disposable infusion device assembly machines, and disposable infusion packaging machines increased compared to the same period last year.